	US 12,454,553 B2
	Antigenic multimeric respiratory syncytial virus polypeptides
Kurt Swanson, Bridgewater, NJ (US); Chih-Jen Wei, Bridgewater, NJ (US); and Gary J. Nabel, Bridgewater, NJ (US)
Assigned to Sanofi, Paris (FR)
Filed by Sanofi, Paris (FR)
Filed on Sep. 29, 2021, as Appl. No. 17/489,249.
Application 17/489,249 is a continuation of application No. PCT/US2020/026198, filed on Apr. 1, 2020.
Claims priority of provisional application 62/828,302, filed on Apr. 2, 2019.
Prior Publication US 2022/0119457 A1, Apr. 21, 2022
Int. Cl. C07K 14/005 (2006.01); A61K 39/00 (2006.01); A61K 39/155 (2006.01); A61P 31/14 (2006.01); C12N 7/00 (2006.01)

CPC C07K 14/005 (2013.01) [A61K 39/155 (2013.01); A61P 31/14 (2018.01); C12N 7/00 (2013.01); A61K 2039/64 (2013.01); A61K 2039/70 (2013.01); C12N 2760/18522 (2013.01); C12N 2760/18534 (2013.01); C12N 2760/18571 (2013.01)]

15 Claims

1. An antigenic RSV G polypeptide comprising more than two RSV G central conserved region (Gcc) monomers and a multimerization domain,

wherein the polypeptide does not comprise ferritin and/or the polypeptide is a single chain polypeptide,

wherein the more than two RSV Gcc monomers comprise RSV Gcc monomers of strain A and strain B,

wherein the RSV Gcc of strain A comprises:

a) the same sequence of amino acids as amino acids 2-42 of SEQ ID NO: 4, or

b) the same sequence of amino acids as amino acids 151-193 of SEQ ID NO: 1;

wherein the RSV Gcc of strain B comprises the same sequence of amino acids as amino acids 10-51 of SEQ ID NO: 8; and

wherein the multimerization domain comprises the sequence of SEQ ID NOs: 9, 11, or 13.